Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$560.14 +0.0%	$581.58	$428.97 ▼ $678.21	$34.20B	0.39	322,665 shs	474,711 shs
BIOVF Swedish Orphan Biovitrum	$29.25	$30.11	$24.08 ▼ $32.25	$10.41B	0.44	61 shs	N/A
IDXX IDEXX Laboratories	$531.32 +0.7%	$499.01	$356.14 ▼ $535.20	$42.73B	1.55	645,765 shs	624,759 shs
VEEV Veeva Systems	$282.89 +0.6%	$255.10	$177.41 ▼ $291.69	$46.31B	0.99	1.15 million shs	1.78 million shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	0.00%	+3.32%	-3.58%	-4.92%	+25.63%
BIOVF Swedish Orphan Biovitrum	0.00%	+8.09%	-3.43%	+1.88%	+6.22%
IDXX IDEXX Laboratories	0.00%	+1.41%	+3.06%	+27.76%	+8.74%
VEEV Veeva Systems	0.00%	+1.29%	+1.45%	+20.84%	+53.58%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARGX argenex	4.2417 of 5 stars	4.5	3.0	0.0	0.0	2.2	1.7	2.5
BIOVF Swedish Orphan Biovitrum	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IDXX IDEXX Laboratories	3.6869 of 5 stars	1.4	4.0	0.0	3.7	3.0	2.5	1.3
VEEV Veeva Systems	4.1684 of 5 stars	2.3	5.0	0.0	2.9	3.4	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARGX argenex	3.05	Buy	$729.93	30.31% Upside
BIOVF Swedish Orphan Biovitrum	4.00	Strong Buy	N/A	N/A
IDXX IDEXX Laboratories	2.78	Moderate Buy	$546.00	2.76% Upside
VEEV Veeva Systems	2.52	Moderate Buy	$269.80	-4.63% Downside

Current Analyst Ratings Breakdown

Latest BIOVF, ARGX, VEEV, and IDXX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	ARGX argenex	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$715.00
6/11/2025	ARGX argenex	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$715.00
6/11/2025	IDXX IDEXX Laboratories	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$515.00 ➝ $580.00
6/10/2025	ARGX argenex	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$720.00
6/2/2025	VEEV Veeva Systems	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$280.00 ➝ $295.00
5/30/2025	VEEV Veeva Systems	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$265.00 ➝ $329.00
5/29/2025	VEEV Veeva Systems	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$285.00 ➝ $300.00
5/29/2025	VEEV Veeva Systems	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$285.00 ➝ $310.00
5/29/2025	VEEV Veeva Systems	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$217.00 ➝ $230.00
5/29/2025	VEEV Veeva Systems	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$250.00 ➝ $285.00
5/29/2025	VEEV Veeva Systems	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$272.00 ➝ $295.00

(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARGX argenex	$2.25B	15.19	$2.97 per share	188.57	$90.49 per share	6.19
BIOVF Swedish Orphan Biovitrum	$2.46B	4.23	$2.05 per share	14.26	$10.71 per share	2.73
IDXX IDEXX Laboratories	$3.90B	10.96	$12.43 per share	42.74	$19.48 per share	27.28
VEEV Veeva Systems	$2.75B	16.83	$4.76 per share	59.43	$38.01 per share	7.44

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARGX argenex	$833.04M	$16.21	34.56	51.63	1.01	40.20%	16.15%	14.33%	7/24/2025 (Estimated)
BIOVF Swedish Orphan Biovitrum	$367.52M	$1.06	27.59	∞	N/A	15.07%	10.54%	5.43%	7/16/2025 (Estimated)
IDXX IDEXX Laboratories	$887.87M	$10.82	49.11	39.13	3.88	22.76%	57.35%	26.97%	8/4/2025 (Confirmed)
VEEV Veeva Systems	$714.14M	$4.72	59.93	60.97	2.21	27.34%	13.96%	11.38%	8/27/2025 (Estimated)

Latest BIOVF, ARGX, VEEV, and IDXX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/24/2025	Q2 2025	ARGX argenex	$2.87	N/A	N/A	N/A	$776.82 million	N/A
5/28/2025	Q1 2026	VEEV Veeva Systems	$1.74	$1.97	+$0.23	$1.37	$728.38 million	$759.04 million
5/8/2025	Q1 2025	ARGX argenex	$2.32	$2.58	+$0.26	$2.58	$748.34 million	$1.35 billion
5/1/2025	Q1 2025	IDXX IDEXX Laboratories	$2.93	$2.96	+$0.03	$2.96	$998.25 million	$998.43 million
4/29/2025	Q1 2025	BIOVF Swedish Orphan Biovitrum	$0.2152	$0.26	+$0.0448	$0.24	$644.12 million	$641.33 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARGX argenex	N/A	N/A	N/A	N/A	N/A
BIOVF Swedish Orphan Biovitrum	N/A	N/A	N/A	N/A	N/A
IDXX IDEXX Laboratories	N/A	N/A	N/A	N/A	N/A
VEEV Veeva Systems	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARGX argenex	N/A	7.29	6.68
BIOVF Swedish Orphan Biovitrum	0.31	1.04	0.71
IDXX IDEXX Laboratories	0.31	1.16	0.81
VEEV Veeva Systems	N/A	4.60	4.60

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARGX argenex	60.32%
BIOVF Swedish Orphan Biovitrum	N/A
IDXX IDEXX Laboratories	87.84%
VEEV Veeva Systems	88.20%

Insider Ownership

Company	Insider Ownership
ARGX argenex	2.43%
BIOVF Swedish Orphan Biovitrum	N/A
IDXX IDEXX Laboratories	0.98%
VEEV Veeva Systems	10.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARGX argenex	1,599	61.06 million	59.58 million	Optionable
BIOVF Swedish Orphan Biovitrum	1,772	356.00 million	N/A	Not Optionable
IDXX IDEXX Laboratories	11,000	80.42 million	79.63 million	Optionable
VEEV Veeva Systems	7,291	163.41 million	146.58 million	Optionable

BIOVF, ARGX, VEEV, and IDXX Headlines

Recent News About These Companies

Veeva Systems Inc. (NYSE:VEEV) Shares Sold by Goodman Advisory Group LLC

2 hours ago | marketbeat.com

Guardian Asset Advisors LLC Acquires New Holdings in Veeva Systems Inc. (NYSE:VEEV)

2 hours ago | marketbeat.com

Veeva Systems Inc. (NYSE:VEEV) Shares Purchased by Achmea Investment Management B.V.

4 hours ago | marketbeat.com

PDS Planning Inc Invests $207,000 in Veeva Systems Inc. (NYSE:VEEV)

4 hours ago | marketbeat.com

Diversified Trust Co Sells 1,585 Shares of Veeva Systems Inc. (NYSE:VEEV)

June 28 at 4:56 AM | marketbeat.com

Perpetual Ltd Invests $4.06 Million in Veeva Systems Inc. (NYSE:VEEV)

June 28 at 4:46 AM | marketbeat.com

Veeva Systems Inc. (NYSE:VEEV) Shares Acquired by Sequoia Financial Advisors LLC

June 28 at 4:27 AM | marketbeat.com

VEEV - Veeva Systems Inc Class A Financials - Morningstar

June 27 at 7:20 PM | morningstar.comM

Veeva (VEEV) Up 0.8% Since Last Earnings Report: Can It Continue?

June 27 at 12:35 PM | zacks.com

Is It Worth Investing in Veeva (VEEV) Based on Wall Street's Bullish Views?

June 27 at 10:31 AM | zacks.com

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Grows Stake in Veeva Systems Inc. (NYSE:VEEV)

June 27 at 6:54 AM | marketbeat.com

Lecap Asset Management Ltd. Lowers Position in Veeva Systems Inc. (NYSE:VEEV)

June 27 at 4:20 AM | marketbeat.com

Asset Management One Co. Ltd. Has $13.84 Million Holdings in Veeva Systems Inc. (NYSE:VEEV)

June 27 at 4:05 AM | marketbeat.com

Amazon.com (NasdaqGS:AMZN) Expands Same-Day Delivery As AWS Partners With Veeva And BeyondTrust

June 26 at 10:11 PM | uk.finance.yahoo.com

Veeva Systems (NYSE:VEEV) Expands AWS Partnership and Enhances Regulatory Management with Veeva RIM

June 26 at 10:11 PM | finance.yahoo.com

Amazon.com (NasdaqGS:AMZN) Expands Cloud Partnership With Veeva To Support Life Sciences

June 26 at 10:11 PM | uk.finance.yahoo.com

Veeva Systems Inc. (VEEV) is Attracting Investor Attention: Here is What You Should Know

June 26 at 10:02 AM | zacks.com

Robeco Institutional Asset Management B.V. Purchases 92,168 Shares of Veeva Systems Inc. (NYSE:VEEV)

June 26 at 6:42 AM | marketbeat.com

Moran Wealth Management LLC Cuts Stock Holdings in Veeva Systems Inc. (NYSE:VEEV)

June 26 at 4:46 AM | marketbeat.com

Veeva Systems Inc. (NYSE:VEEV) Shares Sold by Oppenheimer & Co. Inc.

June 26 at 4:17 AM | marketbeat.com

What Makes Veeva (VEEV) a New Strong Buy Stock

June 25, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIOVF, ARGX, VEEV, and IDXX Company Descriptions

argenex NASDAQ:ARGX

$560.14 +0.10 (+0.02%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$559.98 -0.15 (-0.03%)

As of 06/27/2025 04:04 PM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Swedish Orphan Biovitrum OTCMKTS:BIOVF

$29.25 0.00 (0.00%)

As of 06/27/2025

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Sanofi, Apellis Pharmaceuticals Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.

IDEXX Laboratories NASDAQ:IDXX

$531.32 +3.54 (+0.67%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$523.18 -8.14 (-1.53%)

As of 06/27/2025 06:58 PM Eastern

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Veeva Systems NYSE:VEEV

$282.88 +1.70 (+0.60%)

Closing price 06/27/2025 03:59 PM Eastern

Extended Trading

$284.18 +1.29 (+0.46%)

As of 06/27/2025 07:56 PM Eastern

Veeva Systems Inc. provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States. The company also provides Veeva Development Cloud, a suite of applications for the clinical, regulatory, quality, and safety functions, including Veeva Vault Clinical, Veeva Vault RIM, Veeva Vault Safety, and Veeva Vault Quality; Veeva QualityOne, a quality and document management, and training solution; Veeva RegulatoryOne, a solution that helps companies to manage regulatory submission content; and Veeva Claims addresses the end-to-end product and marketing claims management process. In addition, it offers professional and support services, including implementation and deployment planning and project management; requirements analysis, solution design, and configuration; systems environment management and deployment services; services focused on advancing or transforming business and operating processes related to Veeva solutions; data migration and systems integrations technical consulting services; training on its solutions; and ongoing managed services, such as outsourced systems administration. The company was formerly known as Verticals onDemand, Inc. and changed its name to Veeva Systems Inc. in April 2009. Veeva Systems Inc. was incorporated in 2007 and is headquartered in Pleasanton, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time